JENNIFER FAULKNER-DUPHINEY: Open Payments
NPI 1972284511 · DENVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,589 in 92 payments from 21 companies in 2025. Trend: 2023 $278 · 2024 $1,032 · 2025 $1,589
Food & beverage: $1,589
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $317 |
| Novo Nordisk Inc | 9 | $249 |
| Axsome Therapeutics, Inc. | 11 | $182 |
| PFIZER INC. | 11 | $159 |
| Amgen Inc. | 7 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $110 |
| Lilly USA, LLC | 3 | $50 |
| Janssen Pharmaceuticals, Inc | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 3 | $48 |
Products named: UBRELVY, Wegovy, Auvelity, CAPLYTA, ELIQUIS, OTEZLA, PREVNAR 20, MOUNJARO.
Industry payments across NJ — which companies pay providers there.
